🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "huge turning point" in the effort against drug-resistant strains of the infection, according to scientists.

A Global Public Health Issue

Gonorrhoea infections are escalating globally, with data suggesting more than 82 million new cases annually. Particularly high rates are observed in the African continent and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely development in the face of increasing worldwide cases, escalating drug resistance and the very limited available drugs at this time.”

Health officials are particularly alarmed about the surge in drug-resistant strains. The World Health Organization has designated it as a "priority pathogen". Ongoing monitoring showed that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Secure Approval

One new antibiotic, marketed under the name Nuzolvence, was approved by the US FDA in mid-December for use against gonorrhoea. This disease can lead to major issues, including infertility. Scientists hope that targeted use of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GSK, also received approval in close succession. This drug, which is employed against UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to see it through.

“This milestone signifies a huge turning point in the treatment of multidrug-resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Research Study Data and Global Access

As per findings detailed in a prominent scientific publication, the new drug successfully treated over nine in ten of uncomplicated infections. This establishes an comparable level with the existing first-line therapy, which uses a dual-drug approach. The trial involved nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the authority to register and commercialise the drug in numerous low-income and middle-income countries.

Doctors treating patients have expressed optimism. Having a easy-to-administer therapy like this is seen as a "critical tool" for gonorrhoea control. This is considered essential to reduce the burden of the illness for individuals and to prevent the spread of extremely resistant gonorrhoea globally.